Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446166 | 0.88 | KEAP1 (0.50) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL28572354 | 0.82 | MEN1 (0.55) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL3218436 | 0.79 | HRH3 (0.40) | KMT2ASMN1; SMN2ALDH1A1HRH3 | |
| SCHEMBL731431 | 0.78 | KMT2A (0.51) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL6200 | 0.78 | KMT2A (0.51) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL14194328 | 0.78 | KMT2A (0.51) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL18770758 | 0.78 | KMT2A (0.51) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL4974769 | 0.78 | MEN1 (0.51) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| SCHEMBL426048 | 0.78 | MEN1 (0.51) | KMT2AMEN1GLAKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23753187 | 0.77 | KMT2A (0.50) | KMT2AMEN1GLAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| EP-2298305-A1 | 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | claimed |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8835443-B2 | Pyrimidine compound and medical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2298768-B9 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | JAPAN TOBACCO INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| WO-2005121142-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO’2,3-D! PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC. (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | disclosed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KMT2A 710/4885MEN1 1941/4885GLA 3569/4885 |
| US-20170029418-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KMT2A 710/4885MEN1 1941/4885GLA 3569/4885 |
| US-20200109139-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KMT2A 710/4885MEN1 1941/4885GLA 3569/4885 |
| US-20150183812-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | KMT2A 710/4885MEN1 1941/4885GLA 3569/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | KMT2A 4215/4885MEN1 916/4885GLA 569/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | KMT2A 4308/4885MEN1 1913/4885GLA 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.